83 results about "Hepatocellular Cancers" patented technology

The invention provides a multi-modal large language model for generating a hepatocellular carcinoma key pathological diagnosis report, a framework main body is a visual coding module, and a multi-modal feature alignment module, a multi-head low-rank attention mechanism, an enhanced medical MoE mechanism and a structured output decoding layer are also introduced. The visual coding module is constructed on the basis of a Swin Transform architecture, visual pre-training is completed on hepatocellular carcinoma MRI data, and after a task specific classification head is stripped, a trunk feature extraction network is reserved to serve as an image modal representation encoder. The multi-modal feature alignment module guides the model to learn a cross-modal semantic mapping relation between a hepatocellular carcinoma MRI image and a key pathological diagnosis report language, image modal input is a visual feature sequence, and text modal output is a structured description text; and the structured output decoding layer generates six types of liver cancer focus attributes. According to the method, the pre-operative multi-parameter and multi-stage enhanced MRI image is utilized, and the open-source large model is finely adjusted to generate a matched liver cancer postoperative pathology report.

The invention relates to a gadolinium-doped carbon dot complex based on liver cancer cell membrane coating and a preparation method of the gadolinium-doped carbon dot complex. The gadolinium-doped carbon dot complex is prepared on the basis of gadolinium-doped carbon dots Gd-CDs which are prepared from indocyanine green, citric acid, polyethylene glycol and gadolinic acid through a one-step microwave thermal method and have fluorescence-magnetic resonance bimodal imaging capacity. The Gd-CDs complex Gd-CDs coated HCM is placed in a cell membrane suspension extracted from human hepatoma carcinoma cells HepG2, and the Gd-CDs complex Gd-CDs coated HCM which is uniform in particle size and has the capacity of photothermal and immunotherapy of hepatocellular carcinoma is obtained through extrusion construction of a liposome extruder. The Gd-CDs (at) HCM complex constructed by the invention not only has good bimodal imaging ability, but also has a specific inhibition effect on liver tumor cells, can be applied to preparation of drugs for inhibiting the growth of the liver tumor cells, and realizes a good treatment effect on liver cancer at a nanometer level.

The invention relates to the technical field of hepatocellular carcinoma, in particular to a hepatocellular carcinoma prognosis model construction method based on immunogen cell death related genes and application, and an accurate prognosis prediction model is constructed by integrating the immunogen cell death related genes (IRGs) and molecular characteristics of hepatocellular carcinoma. A training set and a verification set provided by TCGA and ICGC databases are utilized, so that the model can perform effective sample analysis under a large-scale data background. Through consistency clustering analysis, the optimal clustering number is determined, the samples are orderly divided into different molecular subtypes, and it is ensured that the samples in each subtype have similar molecular characteristics. According to the invention, the capability of capturing liver cancer heterogeneity on the molecular level of the model is increased, so that the accuracy of prognosis prediction is improved.

The invention relates to the technical field of microorganisms, and particularly discloses a product for predicting tumor cell occurrence and metastasis risks and treating tumors by using a microbial marker. The cancers related to the invention comprise colon adenocarcinoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, gastric adenocarcinoma, thyroid carcinoma, breast invasive carcinoma, uveal melanoma, esophageal carcinoma and the like. As a marker for predicting the occurrence and metastasis risk of tumor cells. The invention also screens specific microorganisms of healthy tissues relative to tumor tissues as potential means for treating tumors. The screened flora marker is high in sensitivity and good in specificity, and a new method is provided for tumor cell generation and metastasis monitoring and tumor treatment.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or abioequivalent thereof) as neoadjuvant therapy followed by surgical resection and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC), the lung cancer is non-small cell lung cancer (NSCLC), or the head and neck cancer is head and neck squamous cell carcinoma (HNSCC).

The present disclosure provides a new therapeutic target and marker, circBCO2, for inhibiting the progression of liver cancer, especially hepatocellular carcinoma. Inhibition of the expression of circBCO2 or destruction of the signal pathway regulated thereby can serve as a potential therapeutic target for inhibiting the progression of liver cancer. Meanwhile, circBCO2 can also serve as a marker, especially a prognostic marker, for HCC.

A method of inhibiting a cancer cell growth includes contacting the cancer cell with a Cu2(OH)3NO3 / CaSiO3@g-C3N4 nanocomposite material containing graphitic carbon nitride (g-C3N4), copper hydroxide nitrate (Cu2(OH)3NO3) and calcium silicate (CaSiO3), achieving an inhibition efficiency on human breast carcinoma (MCF-7) and human hepatocellular carcinoma (HepG-2) cell growth of greater than 95% in an in-vitro cellular viability assay.

The invention discloses application of a copper carrier in a medicine for enhancing drug resistance of copper death reversing liver cancer cells, and relates to the technical field of medicines. The copper carrier provided by the invention can activate copper death in cisplatin-resistant liver cancer cells in a manner of'three-arrow simultaneous shooting '. The method mainly comprises the following steps: increasing the number of copper ions entering cells (a first'arrow '), consuming GSH to reduce the loss of copper ions in the cells (a second'arrow'), and down-regulating the expression of ATP7B to inhibit the outflow of copper ions (a third'arrow '). Besides, the copper carrier down-regulates copper death related proteins (FDX1, DLAT, ATP7B and LIAS), also down-regulates drug resistance related proteins (ATP7B and P-gp), and shows a remarkable anti-liver cancer curative effect. Particularly, the bCCM can target mitochondria, improve the mitochondrial copper ion level, consume mitochondrial GSH and cause mitochondrial dysfunction mediated by copper death, and the bCCM and the cis-platinum have a remarkable synergistic effect and can reverse the drug resistance of the cis-platinum.

This invention discloses a prognostic and therapeutic suitability assessment model for hepatocellular carcinoma (HCC) based on mRNA vaccine antigens, and its construction method. First, the differences in gene expression between normal tissues and HCC tumors are analyzed to understand the mutations and genomic structural changes in HCC patients. Then, genes related to the level of antigen-presenting cell infiltration, as well as genes significantly related to overall survival and disease-free survival, are further selected from anomalously expressed and mutated genes to obtain candidate mRNA vaccine neoantigen targets. Based on the expression levels of these targets, patients are immunophenotyped to assess the patient population suitable for mRNA vaccines. Simultaneously, the relationship between target expression levels and patient prognosis is quantified to predict the probability of HCC patients achieving 3-year and 5-year overall survival. This invention can objectively and accurately assess treatment resistance and tumor immune status in HCC, improving the predictive accuracy of HCC treatment prognosis.

The present invention relates to systems and methods of processing CT scan images comprising a liver of a subject to detect and / or predict hepatocellular carcinoma (HCC) in the subject.

The invention discloses a cancer cell membrane coated STING agonist loaded MXene compound and a preparation method and application thereof, and belongs to the technical field of biomedical materials.The preparation method comprises the steps that Ti3AlC2 and LiF are mixed, a concentrated hydrochloric acid solution is added, a reaction is conducted for 24-72 h at the temperature of 25-50 DEG C, and then centrifugal washing is conducted to obtain a black precipitate; adding the black precipitate into water, carrying out ultrasonic treatment under the protection of nitrogen to obtain a colloidal solution, and then centrifugally collecting supernate to obtain a d-MXene solution; the preparation method comprises the following steps: mixing a d-MXene solution and an STING agonist solution, stirring at room temperature, reacting in a dark place, adding a micromolecule enhancer containing an amide group into the mixture during the reaction to obtain an STING agonist-loaded MXene compound, and further coating by using a liver cancer cell membrane to obtain a cancer cell membrane-coated STING agonist-loaded MXene compound. The compound has a wide application prospect in the aspect of hepatocellular carcinoma treatment.

The disclosure provides binding agents (e.g., antibodies) against a human Hepatitis A virus cellular receptor 2 protein (TIM3), as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting Non-Small Cell Lung Cancer (NSCLC) and / or other types of lung cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) or other types of liver cancer, Renal cell carcinoma, malignant melanoma, gastro-intestinal cancer, colorectal cancer, urothelial carcinoma and other types of bladder cancer, mamma carcinoma and / or other types of breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, lymphoma / leukemia, malignant mesothelioma, or a cancer in another organ or cell type.

A method of inhibiting cell growth in a cancer includes contacting a graphite-phase carbon nitride copper oxide and magnesium aluminum oxide (g-C3N4@CuO / MgAl2O4) nanocomposite with the cancer to inhibit growth of the cancer. The g-C3N4@CuO / MgAl2O4 nanocomposite comprises a graphite-phase carbon nitride (g-C3N4) in an amount of 2 to 18 percent by weight (wt. %), copper oxide in an amount of 1 to 10 wt. %, and magnesium aluminum oxide (MgAl2O4) in an amount of 75 to 95 wt. % based on a total weight of the g-C3N4@CuO / MgAl2O4 nanocomposite. The cancer includes cells from a cell line selected from a group consisting of a human hepatocellular carcinoma (HepG-2) cell line and a human breast carcinoma (MCF-7) cell line.

The invention belongs to the technical field of biological medicines, and particularly relates to a membrane-coated oncolytic virus as well as a preparation method and application thereof. The oncolytic virus contains a GSDMD N-terminal expression cassette regulated and controlled by a heated shock promoter, and pyroptosis can be induced under exogenous mild thermal stimulation, so that the virus is promoted to be quickly released, and reinfection and amplification of adjacent tumor cells are realized. A bionic nano-vesicle (iNV) formed by a donor cell membrane modified by genetic engineering is used as an outer layer to coat a genetically engineered oncolytic virus (GOV) to obtain a membrane-coated oncolytic virus iNV-GOV, so that the membrane-coated oncolytic virus iNV-GOV simultaneously has immunocompatibility and active tumor recognition capability, is suitable for solid tumors such as pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHCC) and the like, and can be used for preparing an anti-tumor drug. And the tumor volume can be obviously reduced in mouse in-vivo model experiments.

This invention discloses a nanoparticle-based drug delivery system, MPL@ICC, its synthesis method, and its applications. The MPL@ICC system consists of hollow, porous nano-MnO2, a hydrophilic targeting complex on its surface, and an acid-responsive drug, INH-CA, and a photosensitizer loaded internally. It possesses both targeted transport and controlled release capabilities against human hepatocellular carcinoma cells (HepG2), allowing it to accumulate within these cells and achieve photodynamic therapy (PDT) and free radical-induced immune killing within the tumor. Simultaneously, it directly kills tumor cells and transforms them from non-immunogenic to immunogenic, mediating an anti-tumor immune response and achieving immunogenic cell death (ICD). This overcomes the shortcomings of ICD-induced cancer treatment strategies, which often fail to produce strong and durable therapeutic effects, and does not induce normal cell apoptosis, thus possessing controllability, effectiveness, and safety.

The invention relates to application of theaflavin as a UGP2 inhibitor and application of theaflavin in preparation of a medicine for preventing and / or treating hepatocellular carcinoma, and belongs to the technical field of biology. According to the invention, the monomeric compound theaflavin derived from a natural product can be used as a UGP2 direct targeting inhibitor for the first time, and is used for preparing a liver cancer treatment medicine for regulating and controlling glucose metabolism reprogramming. The theaflavin can be specifically and directly combined at a UGP2 active site in a targeting manner through high activity to inhibit the activity of the UGP2, is the first specific inhibitor which takes the UGP2 as a target spot and is reported at present, and can be used for remarkably inhibiting tumor phenotypes such as proliferation, migration and invasion of liver cancer cells by inhibiting UGP2-mediated UDPG synthesis and intracellular glycogen accumulation.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of carbothioamide (and structurally related) small-molecule compounds which function as inhibitors of SIRT5, and their use as therapeutics for the treatment of diseases associated with posttranslational modification functions (e.g., diseases associated with SIRT5 activity) (e.g., cancer (e.g., melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), ovarian cancer, colorectal cancer (CRC), acute myeloid leukemia (AML), Ewing's sarcoma, brain cancer, pancreatic cancer, renal cancer, breast cancer, prostate cancer, lung cancer, leukemia and lymphoma), diabetes, autoimmune diseases, inflammatory diseases, fibrotic diseases, cardiovascular diseases, and neurodegenerative diseases).

The present invention provides a polypeptide targeting HDAC5 and its application in the preparation of a drug for treating cancer. The polypeptide specifically binds to HDAC5, and the polypeptide is selected from any one or more of SEQ ID NOs: 1-5 and SEQ ID NOs: 11-15. By using HDAC5 as the target protein of the anti-cancer drug and combining AI-assisted design and screening methods, a number of novel polypeptide compounds with anti-cancer activity have been found. These polypeptides have the advantages of specific targeting, low toxicity and low side effects as drugs, and thus have potential application value for development as anti-cancer drugs. In particular, when the polypeptide shown in SEQ ID NO: 1 or 11 is used in cell experiments in the form of SEQ ID NO: 6 or 16 with a cell-penetrating peptide, it is found that its anti-hepatocellular carcinoma activity is the highest.

The present technology relates to the field of cancer treatment. In particular, the present technology relates to polypeptides targeting phosphatidylinositolprotein-3 (GPC3) and T cell receptor (TCR) for use in the treatment of phosphatidylinositolprotein-3 positive (GPC3 +) solid tumors, such as hepatocellular carcinoma (HCC) or non-small cell lung cancer (NSCLC). In addition, the technology relates to the dosage of said polypeptide when used as therapy.

The disclosure relates to peptide conjugates specific for Epithelial cell adhesion molecule (EpCAM) and the use thereof to detect and treat epithelial cell-derived cancers such as intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC), breast cancer, colon cancer and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients by detecting expression of EpCAM.

The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.

The application discloses a hepatocellular carcinoma prognosis evaluation method and system based on cell pixel density, and relates to the technical field of hepatocellular carcinoma prognosis evaluation. The method comprises the following steps: acquiring whole slide imaging and performing image preprocessing to determine a critical value of cell pixel level segmentation result; performing cell pixel density calculation according to the critical value of the cell pixel level segmentation result to determine the CD8+TILs density of a tumor area; performing standardization and average calculation processing on the CD8+TILs density of the tumor area to obtain a critical value of ATLS-8; and performing prognosis evaluation on hepatocellular carcinoma of a patient according to the critical value of ATLS-8. By using the application, the cell density on the whole slide can be accurately quantified, the accuracy of cell density measurement is improved, and the accuracy of prognosis evaluation on hepatocellular carcinoma of a patient is improved. The application can be widely applied to the technical field of hepatocellular carcinoma prognosis evaluation.

A kudzuvine flower terpine derivative, a preparation method and application thereof, a structure formula is shown as follows: wherein R1, R2 are H, CH3, CH2F, CHF2, CF3, t-Bu, MOM, EE, THP, a straight chain or branched alkane with carbon atom number being 1-5, an ester group, a silyl ether, a trifluoro or polyfluorinated alkane straight chain terminal alkyne alkane n=1, 2, 3, 4 or 5, m=1, 2, 3, 4, 5 or 6, when one group is a terminal alkyne, the other two groups are alkane or fluorinated alkane. The kudzuvine flower terpine derivative can inhibit the proliferation growth of liver cancer cells, induce liver cancer cell apoptosis and G2 / M cycle arrest, inhibit the migration and invasion of liver cancer cells, achieve the effect of resisting tumors, and provide a new leading drug for clinical treatment of hepatocellular carcinoma.

The invention discloses a prediction model for predicting a liver cancer combined treatment effect based on multi-mode MRI radiomics characteristics and a construction method and application thereof, and belongs to the technical field of liver cancer treatment effect prediction. In order to solve the problem that only part of liver cancer patients can benefit from an arterial chemoembolization combined targeted immunotherapy scheme at present, the invention proposes that before combined therapy, MRI radiomics characteristics and clinical factors are enhanced through noninvasive multi-modal comparison, multiple machine learning models are established, and the model learning model is used for learning the liver cancer patients. The tumor treatment response of arterial chemoembolism combined with molecular targeting and immunotherapy is predicted, and the applicability of the radiomics model is verified by using an external data set; besides, the radiomics model is combined with a clinical model, so that the method has more excellent prediction efficiency, and the radiomics features provide incremental prediction value for clinical factors. According to the method, the combined treatment effect of the liver cancer patients can be predicted, so that more effective and reasonable treatment schemes can be selected for different patients before treatment.

This invention provides an IR820-GPC3-Gd compound and its nanomaterials (IGD NPs) for phototherapy and magnetic resonance imaging of liver cancer, along with their preparation method and applications, belonging to the field of medicinal chemistry. The IR820-GPC3-Gd compound exhibits strong targeting, good phototherapy performance, and stable imaging. The IGD NPs demonstrate excellent active targeting ability for hepatocellular carcinoma (HCC); under 808nm laser irradiation, they exhibit outstanding photothermal and photodynamic properties, making them suitable for treating unresectable HCC. The combined fluorescence imaging and magnetic resonance imaging capabilities of the IGD NPs can precisely locate residual tumor boundaries and provide real-time surgical navigation, improving the conversion therapy efficiency of HCC and ultimately significantly reducing postoperative recurrence rates, providing an effective strategy for tumor downstaging and surgical navigation.

This invention belongs to the field of biomedical technology and provides the application of 16'-DEC in the preparation of anti-hepatocellular carcinoma drugs. This bisindole alkaloid compound can inhibit the proliferation and migration of hepatocellular carcinoma cells and can produce a synergistic anti-tumor effect with lenvatinib, solving the problems of limited efficacy and insufficient patient survival benefit of existing targeted drugs in hepatocellular carcinoma treatment. Experiments have confirmed that 16'-DEC exerts its anti-tumor effect by directly inhibiting mTOR kinase activity. This compound can specifically bind to mTOR protein, significantly upregulate the expression of autophagy-related genes by blocking the mTOR signaling pathway, and induce autophagic cell death in tumor cells. In vitro and in vivo experiments have demonstrated that inhibiting autophagy can reverse the anti-cancer effect of 16'-DEC, indicating that its pharmacodynamic mechanism mainly depends on the activation of the autophagy pathway. This invention is applicable to the development of novel targeted therapies for hepatocellular carcinoma, especially specific inhibitors of the mTOR signaling pathway.

The invention belongs to the technical field of biological medicines, and provides a porphyrin coupled ruthenium (II) complex as well as a preparation method and application thereof. The porphyrin coupled ruthenium (II) complex (PorRu, as shown in the following formula) can be selectively enriched in tumor tissues and is highly specifically combined with G quadruplex (G4) DNA (deoxyribonucleic acid) in a double-lock mode. The dual-binding configuration of PorRu enhances the stability of the structure interacting with DNA, so that more efficient photodynamic activation is realized. When PorRu is combined with G4 DNA and exposed to near-infrared light, high-level active oxygen can be generated, guanine bases are directly oxidized to form 8-oxoguanosine damage, the oxidative damage causes mitochondrial dysfunction and induces pyroptosis, and efficient tumor inhibition is achieved through a synergistic mechanism. The PorRu provides a promising strategy for breaking through the tumor hypoxia barrier, and has huge clinical transformation potential in the field of hepatocellular carcinoma treatment.

The application belongs to the technical field of immunobiology, and particularly relates to a hepatocellular carcinoma antigen peptide and application thereof. The hepatocellular carcinoma antigen peptide provided by the application is a group of shared neoantigens derived from splicing abnormalities, long fragment insertion and deletion or gene fusion mutations, and has the advantages of good safety, high sharing, strong immunogenicity and high tumor specificity. The number of spots produced by the hepatocellular carcinoma antigen peptide has a statistical difference through immunological enzyme-linked immunospot assay, which indicates that the hepatocellular carcinoma antigen peptide has strong immunogenicity. The hepatocellular carcinoma antigen peptide can specifically activate the killing efficiency of induced expanded T cells on tumor cells to be greater than or equal to 30% through tumor cell killing experiment verification, and has a significant tumor killing effect. The hepatocellular carcinoma antigen peptide has great market value when used for preparing a vaccine for preventing and / or treating hepatocellular carcinoma.

The present disclosure relates to novel antibodies or antigen-binding fragments thereof that bind to GPC3. These anti-GPC3 antibodies or fragments thereof preferably comprise no lysine residues in their CDRs, and thus are particularly suitable for conjugation. The present disclosure also relates to targeted radionuclide conjugates, such as targeted actinide 225 conjugate (TAC). Preferably a TAC of formula (I) comprising an anti-GPC3 antibody or fragment thereof of the present disclosure. The antibody or antigen-binding fragment thereof, and / or the antibody conjugate, and / or the TAC can be used in diagnosis and / or therapy, preferably in therapy, more preferably in the treatment of cancer, most preferably in the treatment of hepatocellular carcinoma (HCC). Pharmaceutical compositions comprising these antibodies, functional fragments and conjugates and kits with instructions are provided. The disclosure also provides methods and tools for making these antibodies, functional fragments and conjugates.